#ASCO14 - Poster: Final analysis of a large, open-label global early access protocol with abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy

CHICAGO, IL USA (UroToday.com) - Presented by Cora N. Sternberg,¹ Gedske Daugaard,² Lajos Géczi,³ Sebastien J. Hotte,⁴ Paul N. Mainwaring,⁵ Fred Saad,⁶ Ciro Souza,⁷ Miah H. Tay,⁸ José M. Tello Garrido,⁹ Luca Galli,¹⁰ Anil Londhe,¹¹ Peter De Porre,¹² Dan Atlan,¹³ Betty Goon,¹¹ Emma Lee,¹² Tracy McGowan,¹¹ Vahid Naini,¹⁴ Mary B. Todd,¹⁵ Arturo Molina,¹⁶ and Daniel J. George¹⁷ at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

Click HERE to listen to an exclusive interview with Cora N. Sternberg, MD, one of the authors of the study

¹San Camillo and Forlanini Hospitals, Rome, Italy
²Rigshospitalet, Copenhagen, Denmark
³National Institute of Oncology, Budapest, Hungary
⁴McMaster University, Hamilton, ON, Canada
⁵ICON Cancer Care, Brisbane, Australia
⁶University of Montréal, Montréal, QC, Canada
⁷Center for Oncology, Hospital Sírio-Libanês, São Paulo, Brazil
⁸OncoCare Cancer Centre, Singapore
⁹Centro Oncologico Belenus, Cuernavaca, Mexico
¹⁰University of Pisa, Pisa, Italy
¹¹Janssen Research & Development, Horsham, PA USA
¹²Janssen Research & Development, Beerse, Belgium
¹³Janssen Europe, Paris, France
¹⁴Janssen Research & Development, Los Angeles, CA USA
¹⁵Janssen Global Services, Raritan, NJ USA
¹⁶Janssen Research & Development, Menlo Park, CA USA
¹⁷Duke Cancer Institute, Durham, NC USA